GLAXO — GlaxoSmithKline Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- IN₹390.80bn
- IN₹362.92bn
- IN₹38.22bn
Annual cashflow statement for GlaxoSmithKline Pharmaceuticals, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | 2026 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | IAS | IAS | IAS | IAS | — |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 7,675 | 8,374 | 9,598 | 12,552 | 13,854 |
| Depreciation | |||||
| Non-Cash Items | -243 | -1,085 | -2,543 | -1,352 | -1,317 |
| Discontinued Operations | |||||
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -6.37 | -3,105 | -1,932 | 1,031 | -4,168 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 8,107 | 4,842 | 5,820 | 12,899 | 9,033 |
| Capital Expenditures | -346 | -440 | -312 | -247 | -553 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -3,709 | 8,519 | 399 | -211 | 4,523 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -4,055 | 8,079 | 87.1 | -458 | 3,970 |
| Financing Cash Flow Items | -19.9 | -9.55 | -18 | -13.1 | -27.4 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -5,242 | -15,433 | -5,615 | -7,694 | -7,371 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -1,190 | -2,512 | 292 | 4,747 | 5,632 |